Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: a systematic review and meta-analysis of randomized trials.

Obonska K, Navarese EP, Lansky A, Tarantini G, Rossini R, Kozinski M, Musumeci G, Di Pasquale G, Górny B, Szczesniak A, Kowalewski M, Gurbel PA, Kubica J.

Atherosclerosis. 2013 Aug;229(2):482-8. doi: 10.1016/j.atherosclerosis.2013.04.022. Epub 2013 Apr 24. Review.

PMID:
23672879
2.

Novel oral anticoagulants in acute coronary syndrome.

Costopoulos C, Niespialowska-Steuden M, Kukreja N, Gorog DA.

Int J Cardiol. 2013 Sep 10;167(6):2449-55. doi: 10.1016/j.ijcard.2012.08.014. Epub 2012 Sep 16. Review.

PMID:
22989603
3.

Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome.

Goldstein S, Bates ER, Bhatt DL, Cao C, Holmes D, Kupfer S, Martinez F, Spaeder J, Weitz JI, Ye Z, Zannad F; AXIOM investigators.

Thromb Haemost. 2014 Jun;111(6):1141-52. doi: 10.1160/TH13-07-0543. Epub 2014 Mar 27.

PMID:
24671450
4.

Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).

Mega JL, Braunwald E, Murphy SA, Plotnikov AN, Burton P, Kiss RG, Parkhomenko A, Tendera M, Widimsky P, Gibson CM.

J Am Coll Cardiol. 2013 May 7;61(18):1853-9. doi: 10.1016/j.jacc.2013.01.066. Epub 2013 Mar 7.

5.

New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.

Oldgren J, Wallentin L, Alexander JH, James S, Jönelid B, Steg G, Sundström J.

Eur Heart J. 2013 Jun;34(22):1670-80. doi: 10.1093/eurheartj/eht049. Epub 2013 Mar 6. Review.

7.

Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials.

Komócsi A, Vorobcsuk A, Kehl D, Aradi D.

Arch Intern Med. 2012 Nov 12;172(20):1537-45. doi: 10.1001/archinternmed.2012.4026. Review.

PMID:
23007264
8.

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L.

Circulation. 2009 Jun 9;119(22):2877-85. doi: 10.1161/CIRCULATIONAHA.108.832139. Epub 2009 May 26.

10.

Rivaroxaban in acute coronary syndromes--is it prime time?

Asrar ul Haq M, van Gaal WJ.

Expert Rev Cardiovasc Ther. 2014 Jun;12(6):649-58. doi: 10.1586/14779072.2014.910118. Epub 2014 Apr 19. Review.

PMID:
24746010
11.

Factor Xa inhibitors for acute coronary syndromes.

Brito V, Ciapponi A, Kwong J.

Cochrane Database Syst Rev. 2011 Jan 19;(1):CD007038. doi: 10.1002/14651858.CD007038.pub2. Review.

PMID:
21249686
12.

Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51).

Mega JL, Braunwald E, Wiviott SD, Murphy SA, Plotnikov A, Gotcheva N, Ruda M, Gibson CM.

Am J Cardiol. 2013 Aug 15;112(4):472-8. doi: 10.1016/j.amjcard.2013.04.011. Epub 2013 May 24.

PMID:
23711804
13.

Apixaban with antiplatelet therapy after acute coronary syndrome.

Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L; APPRAISE-2 Investigators.

N Engl J Med. 2011 Aug 25;365(8):699-708. doi: 10.1056/NEJMoa1105819. Epub 2011 Jul 24.

14.

Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials.

Verdoia M, Schaffer A, Barbieri L, Cassetti E, Piccolo R, Galasso G, Marino P, Sinigaglia F, De Luca G.

J Cardiovasc Pharmacol. 2014 Apr;63(4):339-50. doi: 10.1097/FJC.0000000000000052. Review.

PMID:
24336016
15.

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM; ATLAS ACS-TIMI 46 study group.

Lancet. 2009 Jul 4;374(9683):29-38. doi: 10.1016/S0140-6736(09)60738-8. Epub 2009 Jun 17.

PMID:
19539361
16.

Rivaroxaban in patients with a recent acute coronary syndrome.

Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators.

N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13.

17.
18.

Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial.

Cornel JH, Lopes RD, James S, Stevens SR, Neely ML, Liaw D, Miller J, Mohan P, Amerena J, Raev D, Huo Y, Urina-Triana M, Gallegos Cazorla A, Vinereanu D, Fridrich V, Harrington RA, Wallentin L, Alexander JH; APPRAISE-2 Study Group.

Am Heart J. 2015 Apr;169(4):531-8. doi: 10.1016/j.ahj.2014.12.022. Epub 2015 Jan 7.

PMID:
25819860
20.

Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.

Ganetsky VS, Hadley DE, Thomas TF.

Pharmacotherapy. 2014 Jun;34(6):590-604. doi: 10.1002/phar.1375. Epub 2013 Dec 13. Review.

PMID:
24338703

Supplemental Content

Support Center